Application of orientin in preparation of medicine for treating breast cancer

By enhancing tumor immunotherapy with rutin and combining it with PD-L1 inhibitors, the growth of breast cancer was significantly inhibited, which solved the problem of limited efficacy in existing treatments and achieved a higher tumor inhibition rate and enhanced immune factors.

CN121622650APending Publication Date: 2026-03-10HENAN UNIV OF CHINESE MEDICINE
0 Cites 0 Cited by

Patent Information

Application Number
CN202511954825.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-23
Publication Date
2026-03-10

AI Technical Summary

Technical Problem

Existing PD-L1 inhibitors have limited efficacy in breast cancer treatment, facing challenges in patient selection and drug resistance, and their efficacy prediction is inaccurate. There is a need to develop new drug treatment strategies to expand the effective population.

Method used

The use of rutin to enhance tumor immunotherapy significantly increases the infiltration levels of CD8+ T cells and CD4+ T cells in the tumor microenvironment, enhances the expression of immune factors IFN-γ and granzyme B, and is combined with PD-L1 inhibitors to enhance the anti-tumor effect.

Benefits of technology

It significantly inhibits breast cancer tumor growth, with a tumor inhibition rate of 70.0%. The combined treatment effect is better than the superposition of single drug effects. It promotes T cell infiltration and enhances the expression of immune factors, and improves the tumor microenvironment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of orientin in preparation of a medicine for treating breast cancer. An MMTV-PyMT breast cancer transgenic mouse is adopted, it is found that the tumor weight inhibition rate of 31.2% is achieved when the PD-L1 monoclonal antibody is independently used, the inhibition rate of orientin single drug treatment is 25.6%, after the PD-L1 monoclonal antibody and the orientin single drug are jointly used, tumor growth can be remarkably inhibited, the tumor inhibition rate reaches 70.0%, and the combined treatment effect is remarkably superior to simple superposition of the drug effects of all the single drugs. In addition, the combined treatment can also effectively promote the infiltration of CD4 + and CD8 + T cells in tumor tissues, and improve the expression level of key anti-tumor immune factors such as granzyme B (GZMB) and interferon-gamma (IFN-gamma).
Need to check novelty before this filing date? Find Prior Art